Navigation Links
BioAdaptives Prepares for Next Step
Date:7/14/2014

LAS VEGAS, July 14, 2014 /PRNewswire/ -- BioAdaptives, Inc. (OTCBB:BDPT) is pleased to announce Mr. Barry Epling, Chairman has assumed the roles of President and CEO of the Company.  Mr. Epling is the owner of Ferris Holding, Inc., the company that licensed its formulation, intellectual properties, and other technologies to BioAdaptives, Inc. and its financial supporter.

"Mr. Gerald Epling, who has been overseeing BioAdaptives from our early transition as a privately held entity to a public company, has decided to return to the private sector to concentrate on other interests," said Mr. Barry Epling, who went on to say, "We appreciate the dedication of Gerald Epling to the Company and his contributions, he will be missed."

Mr. Barry Epling added, "Due to the success of the human clinical trial on our stem cell activating product and the acceptance in test markets both in the United States and overseas, a stronger involvement under my direct supervision is required. These positive results suggest a number of avenues should be explored to develop a family of products to further the success of the company and offer significant benefits to both humans and animals."

About BioAdaptives, Inc.

BioAdaptives, Inc. is a fully-reporting public company trading on the OTC Bulletin Board under the symbol BDPT. The company is engaged in research and development in science-based nutraceutical products for both human and animal consumption.  The company's focus, in conjunction with Ferris Holding, Inc., is to source high quality, unique raw material worldwide and develop science-based products to improve health and wellness for both humans and animals.  It has also developed a proprietary method that is a non-intrusive bioelectromagnetic device for improving food, beverages, and wellness.

SAFE HARBOR ACT

Forward-Looking Statements: This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of BioAdaptives, Inc its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond BioAdaptives, Inc's ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in BioAdaptives, Inc's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE BioAdaptives, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. The Midwest Prepares to Tackle Gnats with an Unlikely Weapon
2. PAZOO Prepares For First Three National Direct Response Campaigns and Distribution of PAZOO Branded Products
3. MDHI Restocks Inventories - Prepares for Additional Retail Promotions With Americas Largest Discount Warehouse Chain
4. Emdeon Ranked First in Electronic Prescribing Interoperability and EHR Vendor Support for CPOE; Prepares for Stage 2 Meaningful Use
5. Narcolepsy Patient Community Prepares to Share Life Impacts, Treatment Perspectives with FDA Regulators
6. Pharmagen Partners with Bagel Boy Equity Group II, LLC and prepares to Launch its Industry Consolidation Strategy
7. SPO Prepares for Growth in 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... 17, 2017 According to a new market ... Particle Counters), Application (Cleanroom Monitoring, Contamination Monitoring of Liquids), and End ... by MarketsandMarkets, the market is expected to reach USD 330.6 Million ... of 3.7% from 2016 to 2021. ... ...
(Date:2/17/2017)... , Feb. 17, 2017  Perrigo Company plc (NYSE, TASE: ... U.S. Food and Drug Administration for hydrocodone bitartrate and homatropine ... Hydrocodone bitartrate and homatropine methylbromide oral solution ... the symptomatic relief of cough in adults and children 6 ... months ending January 2017 were approximately $16 million.   ...
(Date:2/17/2017)... NEW YORK , Feb. 17, 2017   ... other side effects allegedly associated with use of the ... Philadelphia Court of Common Pleas, ... a mass tort program. According to a notice posted ... scheduled to convene a meeting on March 9, 2017 ...
Breaking Medicine Technology:
(Date:2/18/2017)... ... February 18, 2017 , ... ... the latest information and contact points to easily connect elderly veterans of America's ... living, and elder-care funding. It also conveys material on this year's increase in ...
(Date:2/17/2017)... San Diego, CA (PRWEB) , ... February 17, ... ... new initiative—InvestUp—to focus on foundational and sustainable systems change designed to further positively ... Counties. , “The Board of Trustees has long considered it our duty to ...
(Date:2/17/2017)... Falls Church, VA (PRWEB) , ... ... ... to Integrate FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. ... , What are the critical reimbursement questions manufacturers should be asking ...
(Date:2/17/2017)... WA (PRWEB) , ... February 17, 2017 , ... ... management organizations, has been named a finalist in the 8th Annual DecisionHealth Platinum ... America's healthcare delivery system. Qualis Health’s work is recognized across multiple award categories, ...
(Date:2/17/2017)... Austin, Tx (PRWEB) , ... February 17, 2017 ... ... of revenue cycle management services, announced today that Karen Pilley has been promoted ... expenses is critical in today’s shifting healthcare paradigm – a shift that demands ...
Breaking Medicine News(10 mins):